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ABSTRACT

In most mammals, prolactin (PRL) is essential for
maintaining lactation, and yet the short-term suppression of PRL during established lactation by bromocriptine has produced inconsistent effects on milk
yield in cows and goats. To assess the effect of the
long-term inhibition of PRL release in lactating dairy
cows, 5 Holstein cows in early lactation received daily
intramuscular injections of 1 mg of the PRL-release
inhibitor quinagolide for 9 wk. Four control cows received the vehicle (water) only. During the last week of
the treatments, one udder half was milked once a day
(1×) and the other twice a day (2×). Blood samples
were harvested at milking in wk −1, 1, 4, and 8. The
daily injections of quinagolide reduced milking-induced
PRL release but not the basal PRL concentration. Quinagolide induced a faster decline in milk production,
which was about 5.3 kg/d lower in the quinagolidetreated cows during the last 4 wk of treatment. During
wk 9, the inhibition of milk production by quinagolide
was maintained in the udder half that was milked 2×
but not in the half milked 1×. Milk production was significantly correlated with the quantity of PRL released
at milking. Quinagolide did not affect the release of
oxytocin at milking. Serum concentration of insulinlike growth factor-1 was not affected by treatment or
correlated with milk production. Serum concentrations
of leptin and the calciotropic hormone stanniocalcin
were not affected by the treatment. In conclusion, the
chronic administration of the PRL-release inhibitor
quinagolide decreases milk production in dairy cows.
The effect is likely the result of the reduced release of
milking-induced PRL and is modulated at the level of
the gland by milking frequency.
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INTRODUCTION

As its name implies, prolactin (PRL) is the most
important hormone for the control of lactation. This
hormone is known to be mammogenic and lactogenic
in both monogastric and ruminant mammals. In most
mammals, the suppression of PRL strongly inhibits
lactation (Taylor and Peaker, 1975; Flint and Gardner,
1994). However, the involvement of PRL in the control
of ruminant lactation is less clear. Plaut et al. (1987)
did not observe any increase in milk production by
cows when PRL was injected for 14 d in early lactation,
although another study reported a limited increase in
goats (Knight, 1993). The short-term administration
before parturition of bromocriptine, a dopamine agonist that suppresses PRL release, reduced postpartum
milk production in goats (Forsyth and Lee, 1993) and
cows (Akers, 2002). However, similar treatments applied during established lactation have produced small
or no effects on milk yield (Knight, 1993).
Milking and suckling induce an important increase
in PRL in the blood of the female. This effect is not
related to the milk harvest itself, as it can be induced
in nonlactating animals by nipple stimulation (Akers
and Lefcourt, 1983). This neuroendocrine reflex is
poorly understood, but it is known that the amount of
PRL released decreases as lactation advances (Fuchs
et al., 1984) and that suckling is more efficient than
milking at inducing the reflex (Lupoli et al., 2001).
Although the basal PRL level is not clearly associated
with the amount of milk produced, milking-induced
PRL release is correlated with the level of milk production in both cows and mice (Koprowski and Tucker,
1973; Akers, 2002). In addition, antiapoptotic effects
of PRL have been reported in the mammary gland of
rodents (Travers et al., 1996; Flint et al., 2006) and
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bovine mammary explants (Accorsi et al., 2002). It is
therefore possible that PRL, especially milking-induced
PRL, plays an important role in lactation persistency
by limiting the loss of secretory cells and maintaining
cell differentiation.
Quinagolide is a compound that binds specifically to
the lactotroph dopamine D2 receptor, decreasing the
synthesis and release of PRL (Brownell, 1996). Unlike
the ergot alkaloid bromocriptine, which was used in
early studies on PRL action in cows, quinagolide has
little affinity for serotonin and α-adrenergic binding
sites (Brownell, 1998). In animal models, quinagolide
has a longer half-life, has fewer side effects, and is
200 times more potent than bromocriptine in terms of
inhibiting lactation (Brownell, 1998). Therefore, the
objective of this study was to evaluate whether PRL
is galactopoietic in the bovine by chronically inhibiting
its secretion with quinagolide.
MATERIALS AND METHODS

The ethical aspects of the care of the animals used
in this study were in compliance with the relevant
guidelines and licensing requirements, as defined by
the French Ministry for Agriculture in accordance with
French regulations (Decree No. 2001-464, May 29,
2001).
Experimental Design

Ten multiparous Holstein cows averaging 62 d in
milk were used in this study. The cows were housed
at the Méjusseaume experimental dairy farm of INRA
UMR1080 Production du lait (Le Rheu, France). Cows
were fed ad libitum with a diet containing (on a DM
basis) 65% corn silage, 15% alfalfa silage, 18.5% supplement, and 1.5% mineral supplement. Feed intake and
milk production were recorded daily during the last
2 wk before the initiation of the treatments (pretreatment period) and during the treatment period. Each
cow’s BW was determined in wk −2, 1, 3, 6 and 8 (relative to treatment initiation). During the pretreatment
period and the first 8 wk of the treatments, all quarters
were milked twice daily.
During the 9-wk treatment period, 5 of the cows
received daily (at 1000 h) intramuscular injections of
1 mg quinagolide (Ferring, Wallisellen, Switzerland),
and the other 5 received water injections (control treatment). One control cow was treated for mastitis. She
was removed from the experiment and her data were
discarded. During the last treatment week, differential
milking was applied, with one udder half milked once a
day (1×) and the other twice a day (2×).
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Milk yield was recorded at each milking. During the
differential milking, milk yield was measured and collected by udder halves. Individual milk samples were
collected 3 times a week to determine milk composition.
In addition, aliquots of the milk samples were skimmed
by centrifugation (15 min, 1,000 × g, 4°C) and frozen
once a week. Those samples were used to determine
levels of milk gelatinase [matrix metalloproteinase
(MMP)-2 and MMP-9] activity, BSA, and stanniocalcin-1 (STC-1).
To determine hormonal release, jugular blood samples
were taken in wk −1, 1, 4 and 8. A silastic catheter (Silclear medical-grade silicone tubing, i.d. 1.02 mm, o.d.
2.16 mm; Degania Silicone, Degania Bet, Israel) was
inserted into a jugular vein of each cow the day before
the first blood sampling and remained there for the
duration of the study. The blood samples were taken
before and during a.m. milking (at −2, 1, 2, 5, 10, and
15 min after milking machine attachment) using Monovette syringes coated with EDTA and sodium heparin
(Sarstedt, Nümbrecht, Germany). An additional sample
was collected weekly 1 h after the milking into heparincoated tubes to determine concentrations of glucose,
lactose, urea, NEFA, leptin, and STC-1. Plasma was
separated by centrifugation at 4°C and 3,000 × g for
15 min and then stored at −20°C for later analysis.
Analyses

Milk protein and fat contents were determined by a
commercial laboratory using infrared analysis (Lillab,
Châteaugiron, France). Milk lactose and casein were
determined once a week as described by Hurtaud et
al. (1993). The BSA concentration of the milk was
determined as described by Tremblay et al. (2009).
Milk gelatinase activity was determined using gelatin
zymography, with zymograms performed as described
by Tremblay et al. (2009).
Plasma PRL concentration was measured using an
indirect competitive ELISA (Kollmann et al., 2008).
The intraassay variability was <5% and the interassay
variability was <12%. Plasma concentration of oxytocin
was measured using the enzyme immunoassay method
(Marnet et al., 1994). The detection limit was 7 pg/mL,
the intraassay CV was 7%, and the interassay CV was
8%. Plasma leptin was determined using RIA (Ehrhardt
et al., 2000). The intraassay CV was 5.6%, and the interassay CV was 2.9%. Milk and plasma concentrations
of STC-1 were determined using RIA as described by
De Niu et al. (2000) and validated for bovine STC-1
(Paciga et al., 2002) with inter- and intraassay CV of
8.6 and 7.5%, respectively. Plasma (from EDTA-coated
tubes) concentration of IGF-1 was determined by RIA
(Vicari et al., 2008).
Journal of Dairy Science Vol. 94 No. 3, 2011
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Table 1. Effect of the injection of water (control; n = 4) or quinagolide (1 mg/d; n = 5) for 8 wk on milk
composition in dairy cows1
P-value

Treatment (Trt)
Item

Control

Fat (%)
Fat (kg/d)
Protein (%)
Protein (kg/d)
Lactose (kg/d)
Casein (%)
1
2

4.03
1.52
3.07
1.15
1.78
2.17

Quinagolide
4.18
1.38
3.16
1.04
1.54
2.27

SEM

Trt

0.67
0.25
0.63
0.32
0.60
0.61

2

NS
0.01
NS
0.04
0.03
NS

Trt × time
NS
NS
NS
NS
NS
NS

Data are least squares means for the treatment period.
P > 0.15.

Plasma (from heparin-coated tubes) concentrations
of glucose, urea, NEFA, and lactose were measured on
a multiparameter analyzer (KONE Instruments Corp.,
Espoo, Finland). Commercial kits for glucose (kit glucose hexokinase, Diagnostics, Meylan, France), NEFA
(NEFA C test, Wako, Oxoid, Davdilly, France), urea
(ref. 11703, Thermo Electron, Cergy-Pontoise, France).
and lactose (kit for lactose/d-galactose; Roche Diagnostics, Meylan, France) were used.
Statistical Analyses

Data were analyzed by ANOVA using the MIXED
procedure of SAS (SAS Institute Inc., Cary, NC)
with the REPEATED statement. Time was used as a
repeated effect, and cow(treatment) was used as the
subject. For all variables except oxytocin, the data
obtained during the pretreatment period were averaged and used as a covariate. The amounts of PRL
and oxytocin released into the blood at milking were
calculated by determining the areas under the curves.
Differential milking data from the last 3 d of the period were averaged and analyzed by using the MIXED
procedure with a REPEATED statement. Quinagolide
treatment and milking frequency were the main effects
and cow(treatment) was used as the subject. The effect
of quinagolide treatment within milking frequency was
evaluated with the slice option on the interaction term
in the LSMEANS statement. The relationship between
several parameters was evaluated using the CORR procedure of SAS. Differences were considered statistically
significant when P < 0.05.

cows. The basal PRL concentration was not affected by
the quinagolide treatment.
Milk production declined faster in quinagolide than
control cows (P < 0.05; Figure 1). Milk production of
quinagolide-treated cows was 5.3 kg/d less than that of
control cows during the last 4 wk of treatment. Milk fat
content was not affected by treatment (Table 1). Milk
protein content increased by 10% during the experiment (P < 0.001) but was not affected by treatment
(Table 1). Accordingly, milk fat and protein yields
were decreased (P < 0.01 and 0.05, respectively) in
the quinagolide-treated animals. Lactose content of the
milk was similar for both groups of animals for the first
4 wk, but was reduced (P < 0.05) in the quinagolidetreated animals in wk 5, 6, and 7 (Figure 2). Lactose
yield was also reduced by the quinagolide treatment (P
< 0.05; Table 1). Casein content of the milk was not
affected by the treatment.
The cows treated with quinagolide ate less than the
control cows (P < 0.05), with DMI averaging 22.8 ±
0.5 and 21.1 ± 0.4 kg/d for the control and quinagolide-

RESULTS

The amount of PRL released at milking was reduced
by quinagolide (P < 0.05). In wk 1, 4, and 8, respectively, the amount released averaged 32, 12, and 20% of
the wk −1 amount in the quinagolide-treated cows and
104, 83, and 73% of the wk −1 amount in the control
Journal of Dairy Science Vol. 94 No. 3, 2011

Figure 1. Milk production of dairy cows injected with water
(—♦—; n = 4) or quinagolide (------; 1 mg/d; n = 5) for 8 wk.
Quinagolide significantly reduced milk production (P < 0.05). Data
are presented as least squares means ± SEM.

1305

PROLACTIN INHIBITION AND LACTATION

Figure 2. Lactose concentration in milk from dairy cows injected
with water (—♦—; n = 4) or quinagolide (------; n = 5) for 8 wk.
Quinagolide significantly reduced milk lactose concentration in wk 5,
6, 7 (*P < 0.05) and 8 (†P < 0.1). Data presented are least squares
means ± SEM.

treated cows, respectively. However, the cows in both
groups gained weight, and no treatment effect on BW
was observed (data not shown). Blood concentrations
of NEFA, glucose, and urea averaged 152 ± 28 and 176
± 24 μmol/L; 658 ± 1 and 674 ± 1 mg/L; and 226 ±
12 and 238 ± 11 mg/L for the control and quinagolidetreated cows, respectively. They were not affected by
treatment.
Milking-induced oxytocin release was monitored after
1 wk of treatment and was not affected by treatment (P
> 0.15). For the control and quinagolide-treated cows,
respectively, the amount of oxytocin that was released
averaged 520 ± 78 and 545 ± 107 pg/mL per minute,
and the maximum concentration that was reached averaged 106 ± 37 and 116 ± 34 pg/mL.
Plasma concentration of IGF-1 increased during the
treatment period (P < 0.01) but was not affected by
treatment, averaging 110 ± 10 and 124 ± 9 ng/mL for
the control and quinagolide-treated cows, respectively.
Similarly, plasma concentrations of leptin and STC-1
increased slightly over time (P < 0.05) but were not
affected by treatment, averaging 2.5 ± 0.1 and 2.4 ±

0.1 ng/mL (leptin) and 2.66 ± 0.06 and 2.65 ± 0.05 ng/
mL (STC-1) for the control and quinagolide-treated
cows, respectively. Milk concentration of STC-1 was
not affected by time or the treatment, averaging 0.91
± 0.18 and 1.01 ± 0.15 ng/mL for the control and
quinagolide-treated cows, respectively.
Mammary tight-junction patency was monitored by
analyzing blood lactose and milk BSA concentrations.
Blood lactose was not affected by treatment, averaging
23.0 ± 3.2 and 24.2 ± 2.9 mg/L for the control and
quinagolide-treated cows, respectively. Accordingly,
BSA concentration was lower than the detection limit
(0.1 mg/mL) in the milk samples of 2× udder half for
both control and quinagolide-treated cows, indicating
no opening of the tight junctions (data not shown).
Gelatin zymography showed the presence of proteolytic activity at the apparent molecular weights of
107 kDa in all the milk samples and at 60 kDa in 60%
of the samples. The two proteolytic bands were not
affected by time or treatment (data not shown).
Correlations between endocrine parameters and milk
production were calculated. The highest correlation coefficients were obtained with the amounts (areas under
the curves) and peak values of milking-induced PRL
release (Table 2). Interestingly, the coefficients were
similar in the control and quinagolide-treated cows. No
significant correlations were found between IGF-1 or
STC-1 concentrations and milk production (data not
shown).
Differential milking resulted in a reduction in milk
production in the udder half that was milked 1× (P <
0.001; Figure 3). The inhibitory effect of quinagolide
was maintained in the udder half that was milked
2× (P < 0.05) but was lost in the half milked 1×.
Similarly, the inhibitory effects of quinagolide on milk
protein and fat yields were maintained in the udder
half that was milked 2× (P < 0.05; Table 3) but not in
the half milked 1×. Reducing the milking frequency to
1× caused increases in milk fat contents as well as in
matrix metalloproteinase (MMP)-2 and MMP-9 activity (P < 0.05; Table 3). Milk BSA content were below
the detection limit for 2× quarters but averaged 0.28

Table 2. Correlation between milking-induced prolactin release in blood and milk production1
All animals

Control

Quinagolide

Item

R

P-value

R

P-value

R

P-value

AUC
Peak

0.57
0.56

0.001
0.001

0.64
0.61

0.01
0.02

0.61
0.64

0.005
0.005

2

1

R = Pearson correlation coefficient; AUC = area under the curve.
AUC = area under the curve of prolactin concentration in the plasma during the first 15 min following milking
machine attachment; Peak = maximum prolactin concentration in the plasma during the first 15 min following
milking machine attachment.

2

Journal of Dairy Science Vol. 94 No. 3, 2011
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Table 3. Effect of the injection of water (control; n = 4) or quinagolide (1 mg/d; n = 5) and differential milking [one udder half milked once a
day (1×) and the other milked twice a day (2×)] on milk composition and gelatinase activity in dairy cows
Control
Item
Fat (%)
Fat (kg/d)
Protein (%)
Protein (kg/d)
MMP-23,4
MMP-95

1×
4.74
0.55
3.37
0.38
60.8
133.9

P-value1

Quinagolide
2×

4.17
0.81
3.22
0.62
6.1
98.1

1×
4.50
0.49
3.41
0.37
60.8
112.9

2×
4.28
0.65
3.36
0.52
8.6
103.3

MF
0.03
0.001
0.02
0.001
0.02
0.03

Trt
2

NS
0.02
NS
0.06
NS
NS

Trt × MF
NS
0.20
0.16
0.12
NS
NS

Trt(1×)
NS
NS
NS
NS
NS
NS

Trt(2×)
NS
0.02
NS
0.03
NS
NS

1
MF = milking frequency; Trt = treatment; Trt(1×) or Trt(2×) = effect of quinagolide treatment in the udder half that was milked once a day
or twice a day.
2
P > 0.20.
3
MMP = matrix metalloproteinase.
4
Proteolytic activity (integrated density values × 10−3) at an apparent molecular weight of 60 kDa on a gelatin zymogram.
5
Proteolytic activity (integrated density values × 10−3) at an apparent molecular weight of 107 kDa on a gelatin zymogram.

± and 0.21 mg/mL in 1× quarters for the control and
quinagolide-treated cows, respectively.
DISCUSSION

In this experiment, we observed that the dopamine
D2 receptor agonist quinagolide inhibited milking-induced PRL release in lactating cows. Although already
used in humans for this purpose, quinagolide had never
been tested in cows. The main physiological control
of PRL secretion is exerted by the inhibitory action
of dopamine on the lactotrophs of the anterior pituitary (Torre and Falorni, 2007). Dopamine is secreted
in the hypothalamus through the tuberoinfundibular
dopamine pathway and reaches the pituitary through

Figure 3. Effect of injecting water (white bars; n = 4) or quinagolide (black bars; 1 mg/d; n = 5) and differential milking [one udder
half milked once a day (1×) and the other milked twice a day (2×)]
on milk production of dairy cows. The udder half that was milked 1×
produced less milk than the udder half milked 2× (P < 0.001). The
inhibitory effect of quinagolide was maintained in the udder half that
was milked 2× (P < 0.05) but lost in the half milked 1× (P > 0.15).
Data are presented as least squares means ± SEM.
Journal of Dairy Science Vol. 94 No. 3, 2011

a portal vascular system. It has been proposed that
suckling reduces the activity of the neurons in the
tuberoinfundibular dopamine pathway, enabling the
release of PRL into the bloodstream (Li et al., 1999).
Accordingly, administration of the dopamine antagonist fluphenazine to lactating cows has induced PRL
release with a magnitude comparable to that induced
by milking (Ahmadzadeh et al., 2006).
Quinagolide did not completely prevent milkinginduced PRL release. The dose used in this study
(1 mg/d) was equivalent, on a BW basis, to the dose
used to normalize PRL in hyperprolactinemic women
(0.075 mg/d; Barlier and Jaquet, 2006). With a halflife of 22 h, quinagolide is administered once a day in
women (Barlier and Jaquet, 2006). In the present study,
the cows were injected at 1000 h and PRL concentration was evaluated at milking the following morning
(about 21 h later). If the half-life in cows is in the same
range as in humans, the circulating concentration at
that time would already have been less than half of its
maximum. Therefore, it is likely that inhibition was
greater at the evening milking. Accordingly, greater
inhibition of milking-induced PRL release was observed
when cows were also injected after the evening milking
(Lollivier et al., 2009).
The administration of quinagolide reduced milk
production and yield of milk components. The effect
of another dopamine agonist, bromocriptine, on milk
production was tested previously in dairy ruminants. In
their first experiment, Karg et al. (1972) injected 2 cows
with increasing doses (20 to 160 mg) of bromocriptine
for 3 d and observed an inhibition of PRL without any
effect on milk production. Smith et al. (1974) treated
5 cows with 80 mg of bromocriptine for 2 d without
affecting milk production. In their second experiment,
however, Karg et al. (1972) injected 2 cows for 7 d (5 d
at 150 mg followed by 2 d at 75 mg) and reported a 10
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to 20% decline in milk production. In goats, an early
study did not report an effect of bromocriptine on milk
yield (Hart, 1973), whereas a subsequent study reported
a 21% decrease in milk production after 8 d (Knight et
al., 1990). The inconsistent effects of bromocriptine on
milk production seen in earlier experiments were probably related to the short period of administration and
the very small number of experimental animals.
In the present study, milk production was correlated
with the amount of PRL released at milking, and this
relationship was maintained within each treatment
group. This correlation between milking-induced PRL
release and milk production, previously reported by Koprowski and Tucker (1973), indicates that the effect of
quinagolide on milk production is likely to be mediated
by PRL inhibition. The classical way to demonstrate
the action of a hormone is to remove its source, observe
the changes induced, and try to restore the function by
hormone replacement. In a previous study, hypophysectomy of lactating goats caused a sharp decline in milk
production that required PRL and other hormones to
be restored. Once milk production was back to normal,
however, the PRL treatment could be discontinued
without milk production decreasing again (Cowie et
al., 1964). The logical conclusion of that experiment
was that PRL is lactogenic but not galactopoietic
in goats. However, the goats were given a large dose
(12.5 mg/d) of bovine growth hormone, and its removal
depressed milk production (Cowie et al., 1964). This
growth hormone was pituitary-derived and might have
been contaminated with PRL as reported by Skarda et
al. (1982). Plaut et al. (1987) injected 8 cows for 14 d
with 120 mg of PRL without affecting milk production.
Although the injections increased plasma PRL 2- to
5-fold, they considerably reduced the milking-induced
release of PRL. Conversely, the injection of a much
smaller dose of PRL (1 μg/kg of BW) twice a day for
the first 3 wk of lactation increased milk production
(Wall et al., 2006). In goats, recombinant PRL injections increased milk yield by over 10%, an increase that
was comparable and additive to that elicited by growth
hormone (Flint and Knight, 1997). Further evidence of
the galactopoietic action of PRL is provided by the fact
that a long-day photoperiod was found to increase PRL
concentration and milk production (Bilodeau et al.,
1989), whereas administration of melatonin for 12 wk
decreased PRL and milk production (Auldist et al.,
2007). In all, a good body of evidence now exists indicating that PRL is galactopoietic in dairy ruminants.
The effect of the treatment in the present study was
modulated by milking frequency, with the inhibitory
effect of quinagolide lost in the udder half that was
milked 1×. In goats, a unilateral increase in milking
frequency increased the milk response to PRL admin-
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istration (Knight, 1993). McKinnon et al. (1988) observed that increasing the milking frequency increased
the PRL-binding capacity of the mammary gland.
Accordingly, in cows milked differentially (one udder
half milked 1× and the other 3×), it was observed
that the gene expression of long and short isoforms of
PRL receptors was higher in the glands milked more
frequently (Bernier-Dodier et al., 2010). That suggests
that another important determinant of PRL action is
mammary tissue responsiveness, a conclusion that is
further supported by the fact that a short-day photoperiod during the dry period was found to increase both
the expression of PRL receptors and subsequent milk
production (Auchtung et al., 2005). Nevertheless, it is
also possible that milk accumulation and tight junction
disruption induced by 1× milking may have masked the
treatment-induced responses.
A decrease in feed intake was observed in the
quinagolide-treated cows. The injection of female rats
with bovine PRL increased feed intake and BW gain
(Byatt et al., 1993). The suckling stimulus activates
neuropeptide Y neurons in the dorsomedial nucleus of
the hypothalamus, an effect that is reduced by bromocriptine treatment (Li et al., 1999). Although based
on results from other species, one study proposed that
neuropeptide Y plays an important role in the increase
in feed intake in early lactation (Ingvartsen and Andersen, 2000). It is therefore possible that inhibition of
PRL by quinagolide is responsible for the reduction in
feed intake. The reduced feed intake did not affect BW
gain or blood metabolite concentrations and therefore
probably played a minor role in the reduction of milk
production.
Feuermann et al. (2006) proposed that PRL affects
leptin secretion by the mammary fat pad, which, in
turn, increases the lactogenic action of PRL on mammary epithelial cells. In the present study, the circulating leptin concentration was not affected by the quinagolide treatment. In the lactating bovine mammary
gland, the mammary fat pad is small and not in direct
contact with the epithelium, making the diffusion of a
factor from the fat pad to the epithelial tissue unlikely.
Therefore, the absence of any effect of the PRL inhibitor on the blood leptin concentration does not support
the proposal of Feuermann et al. (2006).
Milk concentration of STC-1 was not affected by quinagolide. Stanniocalcin-1 is a hormone that was first
discovered in fish and recently in mammals (Wagner
et al., 1995). In fishes, PRL and STC-1 have opposing
actions on calcium homeostasis (Flik et al., 1994). In
previous experiments where milk production was reduced by injecting estrogen (Delbecchi et al., 2005), by
unilaterally stopping milking (Tremblay et al., 2009),
or by decreasing milking frequency (Bernier-Dodier et
Journal of Dairy Science Vol. 94 No. 3, 2011
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al., 2010), increased STC-1 in milk was observed. In
those experiments, however, indicators of active involution were also upregulated, suggesting a link between
these STC-1 and involution. In the present experiment,
those indicators were not affected by quinagolide, and
that probably explains why STC-1 was not affected.
Moderate gelatinase activity was detected in milk.
According to Raulo et al. (2002), the 107-kDa band corresponds to MMP-9 and the 60-kDa band corresponds
to MMP-2. These activities have been shown to increase
in milk of the involuting gland during once-a-day milking (Bernier-Dodier et al., 2010), late lactation (Miller
et al., 2006), and milk stasis (Tremblay et al., 2009). In
this experiment, MMP activities were increased by 1×
milking but not by quinagolide. Therefore, it is unlikely
that quinagolide treatment increased the remodeling
of the mammary tissue via metalloproteinase activity
induction.
In conclusion, the data presented here support the
hypothesis that PRL is galactopoietic in dairy cows.
The hormone appears to directly affect the mammary
gland, but the response to PRL appears to be modulated at the mammary gland level by milking frequency.
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